IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma cells

References

• Ma O, Cai WW, Zender L, Dayaram T, Shen J, Herron AJ, et al. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res 2009; 69:2559 - 67; http://dx.doi.org/10.1158/0008-5472.CAN-08-2929; PMID: 19276372
   PubMed Web of Science ®Google Scholar
• Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One 2012; 7:e33778; http://dx.doi.org/10.1371/journal.pone.0033778; PMID: 22457788
   PubMed Web of Science ®Google Scholar
• Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa M, Roth SI, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 2008; 22:1662 - 76; http://dx.doi.org/10.1101/gad.1656808; PMID: 18559481
   PubMed Web of Science ®Google Scholar
• Ando K, Mori K, Verrecchia F, Marc B, Rédini F, Heymann D. Molecular alterations associated with osteosarcoma development. Sarcoma 2012; 2012:523432; http://dx.doi.org/10.1155/2012/523432; PMID: 22448123
   PubMedGoogle Scholar
• Bacci G, Ferrari S, Longhi A, Perin S, Forni C, Fabbri N, et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 2001; 37:32 - 8; http://dx.doi.org/10.1016/S0959-8049(00)00361-0; PMID: 11165127
   PubMed Web of Science ®Google Scholar
• Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 2009; 10:625; http://dx.doi.org/10.1186/1471-2164-10-625; PMID: 20028558
   PubMed Web of Science ®Google Scholar
• Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008; 134:281 - 97; http://dx.doi.org/10.1007/s00432-007-0330-x; PMID: 17965883
   PubMed Web of Science ®Google Scholar
• Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer 2011; 11:125; http://dx.doi.org/10.1186/1471-2407-11-125; PMID: 21481226
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Cesari M, Versari M, Bertoni F. Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients. Cancer 2006; 106:2701 - 6; http://dx.doi.org/10.1002/cncr.21937; PMID: 16691623
   PubMed Web of Science ®Google Scholar
• Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006; 32:423 - 36; http://dx.doi.org/10.1016/j.ctrv.2006.05.005; PMID: 16860938
   PubMed Web of Science ®Google Scholar
• Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25:821 - 52; http://dx.doi.org/10.1146/annurev.immunol.25.022106.141557; PMID: 17201677
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27:485 - 517; http://dx.doi.org/10.1146/annurev.immunol.021908.132710; PMID: 19132915
   PubMed Web of Science ®Google Scholar
• Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004; 21:467 - 76; http://dx.doi.org/10.1016/j.immuni.2004.08.018; PMID: 15485625
   PubMed Web of Science ®Google Scholar
• Bettelli E, Oukka M, Kuchroo VKT. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8:345 - 50; http://dx.doi.org/10.1038/ni0407-345; PMID: 17375096
   PubMed Web of Science ®Google Scholar
• Martin-Orozco N, Dong C. The IL-17/IL-23 axis of inflammation in cancer: friend or foe?. Curr Opin Investig Drugs 2009; 10:543 - 9; PMID: 19513943
   PubMed Web of Science ®Google Scholar
• Ngiow SF, Smyth MJ, Teng MW. Does IL-17 suppress tumor growth?. Blood 2010; 115:2554 - 5, author reply 2556-7; http://dx.doi.org/10.1182/blood-2009-11-254607; PMID: 20339108
   PubMed Web of Science ®Google Scholar
• Ji Y, Zhang W. Th17 cells: positive or negative role in tumor?. Cancer Immunol Immunother 2010; 59:979 - 87; http://dx.doi.org/10.1007/s00262-010-0849-6; PMID: 20352428
   PubMed Web of Science ®Google Scholar
• Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautès-Fridman C, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002; 99:2114 - 21; http://dx.doi.org/10.1182/blood.V99.6.2114; PMID: 11877287
   PubMed Web of Science ®Google Scholar
• Hirahara N, Nio Y, Sasaki S, Minari Y, Takamura M, Iguchi C, et al. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology 2001; 61:79 - 89; http://dx.doi.org/10.1159/000055357; PMID: 11474253
   PubMed Web of Science ®Google Scholar
• Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101:2620 - 7; http://dx.doi.org/10.1182/blood-2002-05-1461; PMID: 12411307
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009; 114:357 - 9; http://dx.doi.org/10.1182/blood-2008-09-177360; PMID: 19289853
   PubMed Web of Science ®Google Scholar
• Honorati MC, Cattini L, Facchini A. Possible prognostic role of IL-17R in osteosarcoma. J Cancer Res Clin Oncol 2007; 133:1017 - 21; http://dx.doi.org/10.1007/s00432-007-0296-8; PMID: 17690908
   PubMed Web of Science ®Google Scholar
• Bajpai J, Sharma M, Sreenivas V, Kumar R, Gamnagatti S, Khan SA, et al. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer 2009; 53:1035 - 9; http://dx.doi.org/10.1002/pbc.22178; PMID: 19621435
   PubMed Web of Science ®Google Scholar
• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41 - 51; http://dx.doi.org/10.1038/nri1995; PMID: 17186030
   PubMed Web of Science ®Google Scholar
• Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A 2012; 109:9623 - 8; http://dx.doi.org/10.1073/pnas.1121606109; PMID: 22623533
   PubMed Web of Science ®Google Scholar
• Lavecchia A, Di Giovanni C, Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr Med Chem 2011; 18:2359 - 75; http://dx.doi.org/10.2174/092986711795843218; PMID: 21568920
   PubMed Web of Science ®Google Scholar
• Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009; 206:1457 - 64; http://dx.doi.org/10.1084/jem.20090207; PMID: 19564351
   PubMed Web of Science ®Google Scholar
• Mantovani A. Role of inflammatory cells and mediators in tumor invasion and metastasis. Cancer Metastasis Rev 2010; 29:241; http://dx.doi.org/10.1007/s10555-010-9228-1; PMID: 20397039
   PubMed Web of Science ®Google Scholar
• Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 2010; 29:243 - 8; http://dx.doi.org/10.1007/s10555-010-9227-2; PMID: 20414701
   PubMed Web of Science ®Google Scholar
• Danese S, Mantovani A. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene 2010; 29:3313 - 23; http://dx.doi.org/10.1038/onc.2010.109; PMID: 20400974
   PubMed Web of Science ®Google Scholar
• Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009; 183:4169 - 75; http://dx.doi.org/10.4049/jimmunol.0901017; PMID: 19767566
   PubMed Web of Science ®Google Scholar
• Chen X, Xie Q, Cheng X, Diao X, Cheng Y, Liu J, et al. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci 2010; 101:2384 - 90; http://dx.doi.org/10.1111/j.1349-7006.2010.01684.x; PMID: 20825419
   PubMed Web of Science ®Google Scholar
• Ren T, Wen ZK, Liu ZM, Liang YJ, Guo ZL, Xu L. Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther 2007; 6:1704 - 9; http://dx.doi.org/10.4161/cbt.6.11.4826; PMID: 17986857
   PubMed Web of Science ®Google Scholar
• Wright JF, Bennett F, Li B, Brooks J, Luxenberg DP, Whitters MJ, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol 2008; 181:2799 - 805; PMID: 18684971
   PubMed Web of Science ®Google Scholar
• Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005; 175:6177 - 89; PMID: 16237115
   PubMed Web of Science ®Google Scholar
• Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y, et al. TLR9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res 2009; 15:623 - 30; http://dx.doi.org/10.1007/s12253-009-9162-0; PMID: 19319670
   PubMed Web of Science ®Google Scholar
• Deodhar SD, James K, Chiang T, Edinger M, Barna BP. Inhibition of lung metastases in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human C-reactive protein. Cancer Res 1982; 42:5084 - 8; PMID: 7139613
   PubMed Web of Science ®Google Scholar